Gurbakhash Kaur

Starting Now: Emerging CAR-T Therapies in T-cell Lymphomas Moderated by: Dr. Stephen Schuster @PennMedicine #DAVAWhistler

Dr. Adolfo Aleman (@IcahnMountSinai) underscores the role of S100A8/A9 in driving T-cell exhaustion in multiple myeloma linked to poorer response and shorter PFS with CAR-T and bispecifics. Neutralization of S100A8/A9 may restore T-cell activity and enhance outcomes. #DAVAWistler

One thing I think about medicine every few months is how certain specialist (such as myself) consciously or subconsciously rely on the intermittent direct expressions of gratitude from patients. But we massively rely on radiology, pathology, IR colleagues (and many others) who operate semi/more “behind the scenes” to the extent it’s unlikely for patients to give the direct praise or know how great of a job they did / how vital they were to a patient’s good outcome (or at least high quality care). To those team members, thank you! (In person gratitude also being expressed, don’t worry!)

Starting Now: Emerging Cellular Therapies in Multiple Myeloma Moderated by: @hhashmi87 @MSKCancerCenter #DAVAWhistler

Starting Now: Multiple Myeloma: Glues and Degraders Moderated by: @TomBmt133 @UCSFCancer #DAVAWhistler

BPd maintenance is being positioned as a strategic shift in high-risk MM post-ASCT, deep responses (≥CR ~68%), high MRD negativity, and early durability signals demonstrated. Presented by Dr. @richaparikh36 from @WinshipAtEmory at #DAVAWhistler

Dr. @ScottG_MD @CityofHope highlights AZD0120's remarkable NDMM data: 100% ORR, 97% sCR & 83% 12-month sustained MRD-negativity with no progression or death at median 36.5 months follow-up. #DAVAWhistler

@DoctorAkrishnan from @cityofhope highlights Talquetamab maintains durable responses even with dose reductions, with manageable skin and nail toxicities and emerging combination strategies shaping future R/R Multiple Myeloma treatment. #DAVAWhistler

Dr. Benjamin Puliafito @MassGenBrigham introduces TriPRIL CAR-T, a novel APRIL-based dual BCMA/TACI-targeting therapy in R/R MM. Phase 1 data shows ORR 85%, CR 54%; including 75% ORR in prior BCMA CAR-T–exposed pts. No Grade ≥3 CRS/ICANS. Dose expansion ongoing. #DAVAWhistler

BCMA strategies in AL by Dr Sandra Mazzoni @ClevelandClinic • Belantamab: ORR ~51% • NXC-201 CAR-T: ↑ responses (~96%), ↑ MRD-neg • ALACRITY: dual-target CAR-T under study • Real-world CAR-T: manageable CRS, ↓ neurotoxicity Field moving toward earlier use. #DAVAWhistler

CELMoD + daratumumab for deep, sustained remission post-transplant! Dr. @Amyloid_Planet @karmanoscancer reviews iberdomide + dara in post-ASCT MM maintenance. IBEX, COMMANDER & Phase 3 EXCALIBER-Maintenance vs. lenalidomide actively enrolling. #DAVAWhistler

Deep, durable remissions & a clean safety profile. Dr. @ForsbergMD @ColoradoBlood showcases iMMagine-1 Phase 2 data on anito-cel (BCMA-directed CAR-T) in RRMM: ORR 96%, sCR/CR 74%, MRD-neg 95%, 24-mo PFS 62%. Global phase 3 IMMagine-3 study underway. #DAVAWhistler

AI is not intelligent. It’s analyzing and stringing together content we generated and repackaging it. Yes, we can use AI wisely to our benefit, and make our lives easier. Like if I’m a doctor, and I need to solve a computer or coding problem, AI is immensely useful and incredibly fast and efficient. But I’m not kidding myself that it’s intelligent. It’s finding and linking and presenting to me information I don’t know that other intelligent humans who do know have generated before.

Talquetamab demonstrates strong bridging efficacy before CAR-T, as @GkaurMD from @MountSinaiNYC reports ORR 71% with rapid responses (~23 days), enabling 89% of patients to proceed to CAR-T and achieving 88% ORR post-infusion. #DAVAWhistler

Are we ready to actively treat smoldering myeloma? Jeffrey Zonder, MD (@Amyloid_Planet, @karmanoscancer, @waynemedicine) reviews genomic heterogeneity (RAS, CNV, APOBEC, MYC) in SMM and AQUILA data (5y PFS 63.1% vs 40.8%; OS ~93% vs 87%). #DAVAWhistler

Scott Goldsmith, MD @ScottG_MD @CityofHope reviews BCMA bispecific antibodies in NDMM: MajesTEC-5 shows 100% ORR & MRD negativity with Tec-Dara induction; LINKER-MM4 & MagnetisMM-6 add promising early data across TE & TIE settings. #DAVAWhistler

Peter Forsberg, MD @ForsbergMD @ColoradoBlood reviews the expanding elranatamab program: MagnetisMM-6 shows 97% ORR with Elra+Dara+Len in TI-NDMM, plus novel combos with iberdomide (MM-30) & upcoming FASTER and ElLen trials in TE-NDMM. #DAVAWhistler

Alfred Garfall, MD @AlGarfall @PennMedicine @PennCancer examines frontline CAR-T in myeloma: consolidation data from CARTITUDE-2 & BMT CTN 1902 show deep MRD negativity, but TCE-based regimens like MajesTEC-5 offer comparable efficacy with greater accessibility. #DAVAWhistler

Quadruplets keep delivering in NDMM: EMN24 (IsKia): Isa-KRd vs KRd → higher MRD-negativity (77% vs 67%) and deeper MRD-10⁻⁶ responses (68% vs 48%), with durable MRD and manageable toxicity. PFS still maturing. #MultipleMyeloma #Myeloma #medtwitter #MMSM rdcu.be/fbVOG

#EMN 24 / Iskia trial is out! Congrats to a terrific team and to the PIs @fra1009 and @AnnemiekBroijl nature.com/articles/s4159…